Research

Metabolic adaptation

GLP-1 RAs demonstrate multisystemic benefits including cardiovascular risk reduction and improved renal outcomes.

Incorporating GLP-1 RAs in treatment plans may enhance overall patient health beyond weight loss.

StrongSupportsmedium confidence
demonstrate multisystemic benefits including cardiovascular risk reduction, improved renal outcomes and treatment of metabolic-dysfunction-associated steatohepatitis.
Matthew Harris et al. · Frontline Gastroenterology · 2026

Why this rating

The claim is based on a synthesis of current evidence presented in the review.

Source

Obesity management medications for the surgeon

Matthew Harris et al. · Frontline Gastroenterology · 2026

DOI 10.1136/flgastro-2025-103307

review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →